JP6784668B2 - 相乗的オーリスタチン組合せ - Google Patents

相乗的オーリスタチン組合せ Download PDF

Info

Publication number
JP6784668B2
JP6784668B2 JP2017518541A JP2017518541A JP6784668B2 JP 6784668 B2 JP6784668 B2 JP 6784668B2 JP 2017518541 A JP2017518541 A JP 2017518541A JP 2017518541 A JP2017518541 A JP 2017518541A JP 6784668 B2 JP6784668 B2 JP 6784668B2
Authority
JP
Japan
Prior art keywords
auristatin
pharmaceutically acceptable
cancer
pi3k
adc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017518541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530983A5 (show.php
JP2017530983A (ja
Inventor
サプラ プヤ
サプラ プヤ
ショア ボリス
ショア ボリス
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2017530983A publication Critical patent/JP2017530983A/ja
Publication of JP2017530983A5 publication Critical patent/JP2017530983A5/ja
Application granted granted Critical
Publication of JP6784668B2 publication Critical patent/JP6784668B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017518541A 2014-10-10 2015-09-29 相乗的オーリスタチン組合せ Active JP6784668B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462062192P 2014-10-10 2014-10-10
US62/062,192 2014-10-10
PCT/IB2015/057457 WO2016055907A1 (en) 2014-10-10 2015-09-29 Synergistic auristatin combinations

Publications (3)

Publication Number Publication Date
JP2017530983A JP2017530983A (ja) 2017-10-19
JP2017530983A5 JP2017530983A5 (show.php) 2018-11-08
JP6784668B2 true JP6784668B2 (ja) 2020-11-11

Family

ID=54288858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518541A Active JP6784668B2 (ja) 2014-10-10 2015-09-29 相乗的オーリスタチン組合せ

Country Status (12)

Country Link
US (1) US10617670B2 (show.php)
EP (2) EP3204005A1 (show.php)
JP (1) JP6784668B2 (show.php)
KR (1) KR20170058432A (show.php)
CN (1) CN107106685A (show.php)
AU (1) AU2015329625B2 (show.php)
BR (1) BR112017006113A8 (show.php)
CA (1) CA2907878A1 (show.php)
IL (1) IL251619B (show.php)
MX (1) MX2017004580A (show.php)
RU (1) RU2717570C2 (show.php)
WO (1) WO2016055907A1 (show.php)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3019559A4 (en) 2013-08-22 2017-04-05 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
KR20250029292A (ko) 2016-04-01 2025-03-04 소니그룹주식회사 초휘도 이량체성 또는 중합체성 염료
RU2753706C2 (ru) 2016-04-06 2021-08-20 Сони Корпорейшн Ультраяркие димерные или полимерные красители со спейсерными линкерными группами
RU2018143594A (ru) 2016-05-11 2020-06-11 Сони Корпорейшн Ультраяркие димерные или полимерные красители
US12018159B2 (en) 2016-07-29 2024-06-25 Sony Group Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same
US12145956B2 (en) 2017-10-05 2024-11-19 Sony Group Corporation Programmable polymeric drugs
US12290571B2 (en) 2017-10-05 2025-05-06 Sony Group Corporation Programmable dendritic drugs
WO2019088176A1 (ja) * 2017-10-31 2019-05-09 国立大学法人神戸大学 抗体薬物複合体効果増強剤
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
WO2019108974A1 (en) * 2017-11-30 2019-06-06 Centurion Biopharma Corporation Albumin-binding prodrugs of auristatin e derivatives
EP3737418B1 (en) 2018-01-12 2024-02-28 Sony Group Corporation Polymers with rigid spacing groups comprising biologically active compounds
US12194104B2 (en) 2018-01-12 2025-01-14 Sony Group Corporation Phosphoalkyl ribose polymers comprising biologically active compounds
EP4137818B1 (en) 2018-03-19 2025-12-10 Sony Group Corporation Use of divalent metals for enhancement of fluorescent signals
US12319817B2 (en) 2018-03-21 2025-06-03 Sony Group Corporation Polymeric tandem dyes with linker groups
JP7580689B2 (ja) 2018-06-27 2024-11-12 ソニーグループ株式会社 デオキシリボースを含むリンカー基を有するポリマー色素
JP7239904B2 (ja) 2019-09-26 2023-03-15 ソニーグループ株式会社 リンカー基を有するポリマータンデム色素
JP7556194B2 (ja) * 2019-12-13 2024-09-26 Ｔｏｐｐａｎホールディングス株式会社 細胞構造体及びその使用
US20240132725A1 (en) 2020-12-07 2024-04-25 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037328A1 (en) 2001-10-30 2003-05-08 Applied Research Systems Ars Holding N.V. Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
DK1725249T3 (en) * 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
JP2009506790A (ja) * 2005-09-07 2009-02-19 メディミューン，エルエルシー 毒素とコンジュゲートしたｅｐｈ受容体抗体
CA2656188A1 (en) 2006-06-26 2008-01-03 Nielsen Media Research, Inc. Methods and apparatus for improving data warehouse performance
CN101573358B (zh) 2006-09-15 2012-05-30 辉瑞产品公司 吡啶并(2,3-d)嘧啶酮化合物及其作为pi3抑制剂的用途
CL2008001334A1 (es) * 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
CA2701155C (en) 2007-10-02 2016-11-22 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient
AP2775A (en) 2008-05-23 2013-09-30 Wyeth Llc Triazine compounds as P13 kinase and MTOR inhibitors
CN119552249A (zh) * 2010-06-08 2025-03-04 基因泰克公司 半胱氨酸改造的抗体和偶联物
CA2815363C (en) * 2010-10-22 2020-07-14 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
MY170719A (en) 2011-04-01 2019-08-27 Wyeth Llc Antibody-drug conjugates
EA201490879A1 (ru) * 2011-10-28 2014-08-29 Дженентек, Инк. Терапевтические комбинации и способы лечения меланомы
HUE053589T2 (hu) * 2011-11-17 2021-07-28 Pfizer Citotoxikus peptidek és azok antitest-hatóanyag konjugátumai
RU2015116480A (ru) * 2012-11-07 2016-12-27 Пфайзер Инк. Анти-notch3 антитела и конъюганты антител с лекарственным средством
DK3137114T3 (da) 2014-04-30 2021-01-25 Pfizer Anti-PTK7-antistof-lægemiddelkonjugater

Also Published As

Publication number Publication date
MX2017004580A (es) 2017-06-27
AU2015329625B2 (en) 2018-04-05
CA2907878A1 (en) 2016-04-10
IL251619B (en) 2020-10-29
RU2017112048A (ru) 2018-11-15
RU2017112048A3 (show.php) 2019-05-07
CN107106685A (zh) 2017-08-29
US20180228769A1 (en) 2018-08-16
BR112017006113A2 (pt) 2017-12-19
WO2016055907A1 (en) 2016-04-14
EP3204005A1 (en) 2017-08-16
BR112017006113A8 (pt) 2018-04-24
JP2017530983A (ja) 2017-10-19
RU2717570C2 (ru) 2020-03-24
KR20170058432A (ko) 2017-05-26
EP3549583A1 (en) 2019-10-09
IL251619A0 (en) 2017-06-29
AU2015329625A1 (en) 2017-04-13
US10617670B2 (en) 2020-04-14

Similar Documents

Publication Publication Date Title
JP6784668B2 (ja) 相乗的オーリスタチン組合せ
JP2024161445A (ja) 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
JP7793556B2 (ja) 抗体－薬物コンジュゲートとａｔｒ阻害剤との組み合わせ
CN108024540B (zh) 用于治疗癌症的方法
JP2025041725A (ja) 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ
KR20120115237A (ko) 암 치료 방법 및 조성물
KR20140025434A (ko) Akt 억제제 화합물 및 화학요법제의 조합물, 및 사용 방법
JP2023539715A (ja) 抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ
JP2023502929A (ja) Ｈｅｒ２陽性乳がんを抗ｈｅｒ２抗体－薬物コンジュゲートと併用してツカチニブで治療する方法
JP2017503842A (ja) 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
JP2017536356A (ja) 肺の非小細胞癌及び多形性膠芽腫を処置するための放射線療法と一緒のジアンヒドロガラクチトール
MX2014010591A (es) Terapia combinada para el tratamiento de cancer de ovario.
AU2019201169A1 (en) Pim kinase inhibitor combinations
CN118450908A (zh) 抗体-药物缀合物和atr抑制剂的组合
CN110996960A (zh) 第三代egfr酪氨酸激酶抑制剂和raf抑制剂的治疗组合
KR20210010524A (ko) 샘낭암종을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물
KR20220008870A (ko) 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
CN114302745A (zh) 包含抗cd19抗体药物缀合物以及pi3k抑制剂或第二剂的组合疗法
HK1242995A1 (en) Synergistic auristatin combinations
WO2025049904A1 (en) Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation
EA049478B1 (ru) Комбинация конъюгата антитела и лекарственного средства и ингибитора atr
HK40054690A (en) Combination of antibody-drug conjugate and kinase inhibitor
Molife et al. 1202 ORAL A Phase I Study of the Potent AKT Inhibitor MK-2206 in Combination With Carboplatin and Paclitaxel, Docetaxel or Erlotinib in Patients With Advanced Solid Tumours

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201020

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201023

R150 Certificate of patent or registration of utility model

Ref document number: 6784668

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250